LoginSignup
Evotec SE Sponsored ADR logo

Evotec SE Sponsored ADR

Stock
Stock
Ticker: EVO
EVO

Price

Price

CHART BY

Frequently asked questions

The market capitalization of Evotec SE Sponsored ADR is $660.33M. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
Evotec SE Sponsored ADR's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$0.753. EPS indicates the company's profitability on a per-share basis.
Currently, 10 analysts cover Evotec SE Sponsored ADR's stock, with a consensus target price of $3.199. Analyst ratings provide insights into the stock's expected performance.
Over the trailing twelve months, Evotec SE Sponsored ADR reported a revenue of $971.89M.
Evotec SE Sponsored ADR's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$48.99M. EBITDA measures the company's overall financial performance.
Evotec SE Sponsored ADR has a free cash flow of -$219.68M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
Evotec SE Sponsored ADR employs approximately 4,553 people. It operates in the Health Care sector, specifically within the Miscellaneous Commercial Services industry.
The free float of Evotec SE Sponsored ADR is 336.82M. Free float refers to the number of shares available for public trading, excluding restricted shares.

Financials

Market Cap 
$660.33M
EPS (TTM) 
-$0.753
Free Float 
336.82M
Revenue (TTM) 
$971.89M
EBITDA (TTM) 
-$48.99M
Free Cashflow (TTM) 
-$219.68M

Pricing

1D span
$1.846$1.934
52W span
$1.80$4.27

Analyst Ratings

The price target is $3.199 and the stock is covered by 10 analysts.

Buy

3

Hold

7

Sell

0

Information

Evotec SE is a life science company, which engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. It operates through the Shared R&D and Just–Evotec Biologics segments. The Shared R&D segment includes drug discovery and development services and solutions. The Just–Evotec Biologics segment provides services related to designing, discovering, developing, and manufacturing of modern biotherapeutics. The company was founded by Manfred Eigen, Karsten Henco, Ulrich Aldag, Freimut Leidenberger, Heinrich Maria Schulte, Rudolf Rigler, Charles Weissmann, and Nobel Laureate on December 8, 1993 and is headquartered in Hamburg, Germany.

Employees
4,553
Industries
Miscellaneous Commercial Services
Sector
Health Care

Identifier

Primary Ticker
EVO

Knockouts

Real-time data from LSX · Fundamentals & EOD data from FactSet
Join the conversation
Sign upLogin